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Objective: To assess the responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP)
measure, Hip Disability and Osteoarthritis Outcome Score Physical Function Short Form (HOOSePS), and
the Knee Disability and Osteoarthritis Outcome Score Physical Function Short Form (KOOSePS) in
a pharmacological trial.
Methods: Data were obtained from a randomized double-blind trial comparing naproxcinod with nap-
roxen and ibuprofen in individuals with hip or knee osteoarthritis (OA) (NCT00662896). Participants
completed the ICOAP, HOOSePS/KOOSePS, and Western Ontario and McMaster Universities OA Index
(WOMAC) Likert version 3.0 before and 13 weeks after treatment. In hip and knee OA participants
separately, the mean pre-post treatment change in scores, effect size (ES) and standardized response
mean (SRM) were determined for each measure by treatment arm, and for all arms combined.
Results: Of 349 trial participants, 156 with knee OA and 48 with hip OA completed all measures at both
time-points and were included (mean age 61 years; two-thirds female). Although there was both within
treatment and between treatment variability in response, among knee OA participants, ICOAP inter-
mittent, constant, and total scores and KOOSePS scores showed, on average, moderate effects, with ESs
ranging from 0.46 to 0.54 and SRMs from 0.49 to 0.56. Similar changes were seen for the WOMAC pain
and function subscales (0.58 and 0.58, respectively). In those with hip OA, no signiﬁcant improvement in
symptoms was seen for any measure.
Conclusion: Responsiveness to pharmaceutical intervention was demonstrated for ICOAP and KOOSePS
among participants with knee OA. Absence of treatment response precluded assessment of respon-
siveness in hip OA.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the leading cause of joint pain and physical
disability with substantial effects on quality of life and use of health
care services1. Current treatment for OA focuses on achieving pain
relief, with downstream beneﬁts on functional limitations, sleep2,o: Gillian Hawker, Women’s
15, Toronto, ON, Canada M5S
).
s Research Society International. Pfatigue3, and mood4,5, using a variety of pharmacological and
non-pharmacological therapies6. A number of patient-reported
outcome measures have been used to evaluate changes in pain
and physical disability in hip and knee OA as a result of pharma-
cologic interventions. Perhaps most widely used has been the
Western Ontario and McMaster Universities OA Index (WOMAC)7,
comprised of three subscales, one each for pain, stiffness, and
physical function. An 11-item short-form version of the WOMAC
function scale has also been developed and assessed for reliability,
validity and responsiveness8,9. However, recognized limitations of
the WOMAC include the high correlation between pain and phys-
ical function subscale scores (pain items largely evaluate painublished by Elsevier Ltd. All rights reserved.
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ment of pain and disability as independent constructs10,11. Studies
have consistently failed to demonstrate the factorial validity of the
WOMAC12,13. Finally, qualitative research has raised concerns about
the adequacy of existing OA pain measures, including the WOMAC,
to comprehensively evaluate the pain experience in OA14.
To address these issues, under the auspices of an Osteoarthritis
Research Society InternationaleOutcome measures in Rheuma-
tology (OARSIeOMERACT) initiative, three new measures have
been developed to evaluate pain and function in hip and knee OA:
the Intermittent and Constant Osteoarthritis Pain (ICOAP) Score14,
the Hip Disability and Osteoarthritis Outcome Score Physical
Function Short Form (HOOSePS)15, and the Knee Disability and
Osteoarthritis Outcome Score Physical Function Short Form
(KOOSePS)16. The ICOAP is an 11-item scale for assessment of hip or
knee OA pain, which was developed from content analysis of
qualitative interviews in individuals with painful hip or knee
OA14,17. ICOAP evaluates two pain domains: a ﬁve-item scale eval-
uates constant pain (intensity and impact on mood e two items,
sleep and quality of life); and a six-item scale evaluates intermittent
pain or ‘‘pain that comes and goes’’ (same items as for constant
subscale plus an item assessing pain frequency). Item responses are
from ‘not at all’ (zero) to ‘extremely’ (four) or ‘never’ (zero) to ‘very
often’ (four)17. Subscale scores are created by summing item scores
and normalizing from 0 (no pain) to 100 (extreme pain). A total
ICOAP score is calculated by summing the subscale scores. In a hip/
knee OA cohort aged 40þ, ICOAP was found to be internally
consistent (Cronbach’s alpha 0.93) and reliable (testeretest reli-
ability intraclass correlation coefﬁcient 0.85)17. Descriptive analyses
demonstrated good distribution of response options across all
items and discrimination of the two types of pain17. Total and
subscale ICOAP scores were signiﬁcantly correlated with scores on
the WOMAC pain scale, the KOOS symptoms scale, and self-rated
effect of hip/knee problems on quality of life, with Spearman
correlation coefﬁcients ranged in magnitude from 0.60 (KOOS
symptoms) to 0.81 (WOMAC pain scale)17. Correlations between
ICOAP scores and WOMAC function were lower than those for
WOMAC pain with WOMAC function, indicating that the two
measures are evaluating different constructs.
The HOOSePS and KOOSePS were developed from the Activities
of Daily Living subscale (which subsumes the 17 physical function
items of the WOMAC Likert 3.0) and the Sport and Recreation
subscale of the HOOS and the KOOS, respectively18,19. The latter
were designed to evaluate a broader spectrum of physical function
impairments in people with hip and knee OA than has been
previously demonstrated using the WOMAC. The short-form
versions were derived from Rasch analysis of data from individ-
uals aged 19e96 years with hip and knee OA, respectively, from
multiple countries across a breadth of disease severity ranging from
community to pre-total joint replacement samples. The short-form
HOOS is comprised of ﬁve items, which assess level of difﬁculty
performing the following activities: sitting, descending stairs,
getting in/out of bath or shower, twisting/pivoting on loaded leg,
and running. The short-form KOOS is comprised of seven items,
which assess level of difﬁculty with rising from bed, putting on
socks/stockings, rising from sitting, bending to the ﬂoor, twisting/
pivoting on your injured knee, kneeling and squatting. In joint
replacement recipients, internal consistency using Cronbach’s
alpha was 0.79 and 0.89 for the HOOSePS and KOOSePS, respec-
tively. Correlations of the HOOSePS and KOOSePS with the
WOMAC 17-item physical function subscale were both 0.90 and
0.85 with the WOMAC physical function excluding items common
to the short measures20.
The current study evaluated the responsiveness of these
measures in the context of a double-blind, randomized, controlledclinical trial comparing the effects of naproxcinod 750 and 375 mg
bid, equimolar amounts of naproxen (500 mg and 250 mg bid,
respectively), and ibuprofen 600 mg tid on blood pressure, pain
and disability in patients with hip and knee OA. Naproxcinod is a
cyclooxygenase-inhibiting nitric-oxide (NO) donator with analgesic,
anti-inﬂammatory, antipyretic and NO-donating properties21; prior
studies have found naproxcinod to be non-inferior to naproxen and
ibuprofen in relieving pain and improving physical function in OA as
measured using the WOMAC21e23. The current study evaluated the
responsiveness of the ICOAP, HOOSePS, and KOOSePS to changes
in pain and disability following pharmacologic intervention.
Methods
Study subjects were participants in a 13-week, phase I double-
blind, randomized, naproxen- and ibuprofen-controlled parallel
group, multicenter trial, conducted in the United States, that
compared the effects of naproxcinod to naproxen and ibuprofen on
blood pressure, pain and disability in individuals with painful hip
and knee OA and well-controlled hypertension (NCT00662896).
Participants were randomly allocated to one of ﬁve study arms;
naproxcinod 750 mg, naproxcinod 375 mg, naproxen 500 mg,
naproxen 250 mg, or ibuprofen 600 mg in a 1:1:1:1:1 ratio for
13 weeks duration. Eligible participants were individuals aged
40þ years with diagnosed hip or knee OA and OA-related pain
for at least 3 months. All participants had controlled essential
hypertension on one antihypertensive medication (diuretic,
angiotensin-converting enzyme inhibitor, angiotensin receptor
blocker or beta-blocker) and were current chronic users of non-
steroidal anti-inﬂammatory drugs or acetaminophen. Participants
discontinued all prior analgesic therapy at screening. Individuals
with uncontrolled diabetes, prior gastric or duodenal ulceration or
history of gastro-duodenal bleeding, hepatic or renal impairment,
drug/alcohol abuse, congestive heart failure, clinically relevant
abnormal electrocardiogram, current or expected use of anticoag-
ulants and/or participating in another investigational study within
30 days of pre-screening were excluded. The pre-speciﬁed primary
trial outcome was the mean change from baseline in 24-h arterial
blood pressure as measured using ambulatory blood pressure
monitoring. The WOMAC, ICOAP, HOOSePS (hip OA patients) and
KOOSePS (knee OA patients) were included as exploratory
endpoints. Participants were assessed by interview prior to and at
13 weeks post-randomization. Participants were asked to complete
relevant data for only their most painful hip or knee, as determined
at the initial visit. For all measures, scores were standardized to
0e100 with higher scores indicating greater pain or disability.
Statistical analysis
Statistical analyses were restricted to participants with
complete data for all measures at both the initial and 13-week
assessments, conducted separately for hip and knee OA partici-
pants, and performed by treatment group as well as for the ﬁve
study arms combined. Descriptive data for the hip and knee
samples were calculated, separately, using means, medians and
proportions, as appropriate. Pearson correlations between baseline
scores for all measures (ICOAP subscale and total scores, HOOSePS,
KOOSePS, and WOMAC Likert-type version 3.0 pain and function
subscale scores) were calculated. For each measure we also calcu-
lated: the mean and standard deviation (SD) of change in scores
from baseline to follow-up; the effect size (ES; mean change in
scores divided by the SD of baseline scores); and the standardized
response mean (SRM; mean change in scores divided by the SD of
the mean change). The 95% conﬁdence intervals (CIs) for the ES and
SRM were determined using bootstrapping, with 1000 bootstrap
Table I
Study sample characteristics
Demographic characteristics Knee N ¼ 156 Hip N ¼ 48
Age e mean (SD) 61.2 (9.2) 60.3 (9.4)
Female e n (%) 107 (68.6%) 33 (68.8%)
Caucasian e n (%) 129 (82.7%) 40 (83.3%)
OA symptom duration (years) e
median (inter-quartile range)
7.4 (3.2e12.9) 6.4 (2.5e10.4)
Most painful joint e n (%)
Right 102 (65.4%) 27 (56.25%)
Left 54 (34.6%) 21 (43.75%)
Treatment arm e n (%)
1 33 (21.15%) 8 (16.7%)
2 36 (23.1%) 10 (20.8%)
3 28 (17.95%) 12 (25.0%)
4 33 (21.15%) 8 (16.7%)
5 26 (16.7%) 10 (20.8%)
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ered low if values were0.3, large for values0.8 andmoderate for
intermediate values. Differences in mean pre-post treatment scores
were assessed using paired t-tests. Variability in response by
treatment arm was assessed using analysis of variance.Results
Sample characteristics
Of 349 individuals who were randomized, 204 had complete
data for all measures at both time-points and were included in
these analyses. Of these 204 participants, themost painful joint was
a knee for 156 (76.5%) and a hip for 48 (23.5%). The characteristics of
hip and knee participants were similar; mean age was 61.2 and
60.3 years, respectively; more than two-thirds were female (68.6%
and 68.8%, respectively) and Caucasian (82.7% and 83.3%, respec-
tively) (Table I).Correlations between measures
All measures were signiﬁcantly correlated (P< 0.001). However,
for both hip and knee OA participants, the correlations between
WOMAC pain and function subscale scores were higher (0.91 for
knees; 0.89 for hips) than were the correlations between ICOAP
subscale or total scores with KOOSePS (Pearson’s r ¼ 0.57e0.62),
HOOSePS (r ¼ 0.51e0.62), or WOMAC function (r ¼ 0.76e0.81 for
knees; r ¼ 0.75e0.79 for hips) (Table II).Table II
Pearson correlation coefﬁcients between pre-treatment scores*
WOMAC
pain
ICOAP intermittent
pain
Knee OA (n ¼ 156)
WOMAC pain 1.00 0.79
ICOAP intermittent pain 0.79 1.00
ICOAP constant pain 0.75 0.81
ICOAP total 0.81 0.95
WOMAC function 0.91 0.78
KOOSePS 0.55 0.61
Hip OA (n ¼ 48)
WOMAC pain 1.00 0.78
ICOAP intermittent pain 0.78 1.00
ICOAP constant pain 0.76 0.80
ICOAP total 0.81 0.95
WOMAC function 0.89 0.75
HOOSePS 0.68 0.62
*P values < 0.0001.Responsiveness of the measures
Knee OA participants
Pooling all treatment arms, therewas a signiﬁcant improvement
in both pain and function measures following treatment
(P < 0.0001) (Table III). However, signiﬁcant within and between-
treatment group variability in response was observed. This
reached statistical signiﬁcance only for knee function measures
(WOMAC function, P ¼ 0.008; KOOSePS, P ¼ 0.02). ICOAP inter-
mittent, constant, and total scores showed moderate ESs
(0.46e0.54), with SRMs between 0.49 and 0.56, overall. Across
treatment groups, ESs ranged from 0.24 to 0.61 (constant scale),
0.19e0.96 (intermittent scale) and 0.22e0.81 (total score). SRMs
varied similarly. The WOMAC pain subscale showed a similar
moderate ES (0.55) and SRM of 0.58, overall, and similar variability
across treatment arms, with ES values from 0.26 to 0.79 and SRM
values from 0.30 to 0.94. Physical function scores using the
KOOSePS and WOMAC physical function subscale showed
comparable results with, on average, moderate ESs (0.53 and 0.52,
respectively) and SRMs of 0.52 and 0.58, respectively, but with
signiﬁcant variability across treatment groups as noted above.
Hip OA participants
Non-signiﬁcant changes were seen for all measures following
treatment among hip OA participants, both overall and across
treatment groups (Table II). The corresponding ESs and SRMs were
non-signiﬁcant for all measures, but once again varied substantially
across treatment arms.Discussion
In a ﬁve arm randomized trial comparing three active phar-
macologic agents on blood pressure in individuals with hip and
knee OA, the new OARSIeOMERACT pain and function measures
were found to be responsive to pre-post treatment changes in pain
and disability in participants with knee but not hip OA. For both the
new measures and WOMAC pain and function subscale scores, no
signiﬁcant treatment response was observed among hip OA
patients overall, or by treatment arm. However, sample size per
treatment arm was small within the hips OA group, potentially
limiting power to detect signiﬁcant pre-post change in symptoms.
These ﬁndings complement those of previous studies, which
documented the responsiveness of ICOAP and HOOSePS/KOOSePS
to changes in pain and function, respectively, following total joint
replacement surgery20,25.ICOAP constant
pain
ICOAP
total
WOMAC
function
KOOSePS/
HOOSePS
0.75 0.81 0.91 0.55
0.81 0.95 0.78 0.61
1.00 0.95 0.76 0.57
0.95 1.00 0.81 0.62
0.76 0.81 1.00 0.57
0.57 0.62 0.57 1.00
0.77 0.81 0.89 0.68
0.80 0.95 0.75 0.62
1.00 0.95 0.75 0.51
0.95 1.00 0.79 0.59
0.75 0.79 1.00 0.71
0.51 0.59 0.71 1.00
Table III
Baseline and mean change in scores, effect sizes and standardized response means for pain and function measures
Measure Baseline mean
scores (SD) (minemax)
Mean change
(SD)
Effect size (95% CI) Standardized response
mean (95% CI)
Knee OA (n ¼ 156) (n per treatment group: 1 n ¼ 33, 2 n ¼ 36, 3 n ¼ 28, 4 n ¼ 33, 5 n ¼ 26) e PAIN
ICOAP Constant (ﬁve arms combined) 40.7 (22.5) 10.3 (21.1)* 0.46 (0.61 to 0.32) 0.49 (0.65 to 0.34)
Trial arm 1y 42.4 (20.9) 9.4 (21.5)*** 0.45 (0.95, 0.12) 0.44 (0.84, 0.12)
Trial arm 2 44.6 (22.9) 11.4 (21.1)** 0.50 (0.86, 0.18) 0.54 (0.95, 0.23)
Trial arm 3 36.6 (21.1) 8.0 (23.1) 0.38 (0.80, 0.03) 0.35 (0.76, 0.02)
Trial arm 4 41.5 (26.4) 16.2 (21.7)** 0.61 (0.91, 0.39) 0.75 (1.05, 0.52)
Trial arm 5 36.35 (20.0) 4.8 (16.8) 0.24 (0.58, 0.09) 0.29 (0.76, 0.10)
Intermittent (ﬁve arms combined) 48.3 (20.1) 10.9 (19.9)* 0.54 (0.72 to 0.38) 0.55 (0.75 to 0.38)
Trial arm 1 50.1 (18.5) 12.0 (25.2)** 0.65 (1.27, 0.19) 0.48 (0.96, 0.14)
Trial arm 2 49.0 (21.35) 9.0 (16.95)** 0.42 (0.83, 0.16) 0.53 (1.06, 0.20)
Trial arm 3 46.4 (20.4) 9.2 (20.0)*** 0.45 (0.97, 0.09) 0.46 (0.94, 0.09)
Trial arm 4 53.0 (19.9) 19.1 (16.5)* 0.96 (1.41, 0.65) 1.15 (1.54, 0.89)
Trial arm 5 41.0 (19.6) 3.7 (17.3) 0.19 (0.58, 0.17) 0.21 (0.64, 0.18)
Total (ﬁve arms combined) 44.8 (20.2) 10.6 (18.8)* 0.53 (0.68 to 0.39) 0.56 (0.74 to 0.41)
Trial arm 1 46.6 (18.0) 10.8 (22.1)** 0.60 (1.11, 0.17) 0.49 (0.97, 0.14)
Trial arm 2 47.0 (21.4) 10.1 (16.9)** 0.47 (0.80, 0.20) 0.60 (1.09, 0.24)
Trial arm 3 42.0 (19.4) 8.7 (19.7)*** 0.45 (0.86, 0.09) 0.44 (0.89, 0.08)
Trial arm 4 47.8 (21.9) 17.7 (16.9)* 0.81 (1.12, 0.61) 1.05 (1.42, 0.88)
Trial arm 5 38.9 (19.35) 4.2 (16.6) 0.22 (0.56, 0.10) 0.25 (0.70, 0.10)
WOMAC pain Five arms combined 45.0 (21.6) 11.8 (20.5)* 0.55 (0.72 to 0.40) 0.58 (0.75 to 0.43)
Trial arm 1 49.4 (20.2) 15.9 (21.3)** 0.79 (1.27, 0.46) 0.75 (1.09, 0.47)
Trial arm 2 45.6 (22.0) 8.6 (20.3)*** 0.39 (0.76, 0.10) 0.42 (0.77, 0.12)
Trial arm 3 42.7 (20.2) 10.2 (21.8)*** 0.50 (0.96, 0.12) 0.47 (0.92, 0.11)
Trial arm 4 46.0 (22.4) 17.2 (18.1)* 0.77 (1.15, 0.48) 0.94 (1.37, 0.64)
Trial arm 5 39.5 (23.3) 6.0 (19.9) 0.26 (0.62, 0.095) 0.30 (0.73, 0.10)
Knee OA (n ¼ 156) (n per treatment group: 1 n ¼ 33, 2 n ¼ 36, 3 n ¼ 28, 4 n ¼ 33, 5 n ¼ 26) e FUNCTION
WOMAC function Five arms combined 47.7 (22.7) 11.8 (20.4)* 0.52 (0.68 to 0.37) 0.58 (0.74 to 0.42)
Trial arm 1 52.3 (21.0) 15.85 (22.9)** 0.76 (1.27, 0.39) 0.69 (1.01, 0.41)
Trial arm 2 46.0 (23.3) 6.1 (16.7)*** 0.26 (0.55, 0.03) 0.37 (0.73, 0.04)
Trial arm 3 45.6 (23.2) 9.3 (21.3)*** 0.40 (0.75, 0.08) 0.44 (0.90, 0.08)
Trial arm 4 51.5 (22.0) 20.8 (20.3)* 0.94 (1.47, 0.61) 1.02 (1.47, 0.73)
Trial arm 5 41.9 (23.8) 5.0 (16.3) 0.21 (0.50, 0.07) 0.31 (0.80, 0.08)
KOOSePS Five arms combined 42.3 (13.0) 6.8 (13.1)* 0.53 (0.72 to 0.36) 0.52 (0.68 to 0.36)
Trial arm 1 48.0 (15.9) 11.2 (16.0)** 0.71 (1.17, 0.36) 0.70 (1.08, 0.39)
Trial arm 2 39.8 (13.0) 4.4 (13.3) 0.34 (0.75, 0.03) 0.33 (0.75, 0.03)
Trial arm 3 38.7 (12.1) 4.9 (8.8)** 0.40 (0.97, 0.12) 0.56 (1.13, 0.15)
Trial arm 4 44.3 (11.0) 10.6 (12.3)* 0.96 (1.55, 0.65) 0.86 (1.17, 0.61)
Trial arm 5 39.7 (9.95) 1.7 (11.3) 0.18 (0.74, 0.27) 0.16 (0.65, 0.25)
Hip OA (n ¼ 48) (n per treatment group: 1 n ¼ 8, 2 n ¼ 12, 3 n ¼ 12, 4 n ¼ 8, 5 n ¼ 10) e PAIN
ICOAP Constant (ﬁve arms combined) 35.4 (22.7) 4.2 (23.95) 0.18 (0.50 to 0.12) 0.17 (0.50 to 0.11)
Trial arm 1 38.75 (16.4) 9.4 (10.5)*** 0.57 (5.08, 0.14) 0.89 (2.02, 0.50)
Trial arm 2 46.0 (20.4) 7.0 (32.9) 0.34 (2.03, 0.81) 0.21 (1.23, 0.49)
Trial arm 3 22.9 (21.4) 2.9 (25.7) 0.14 (0.88, 0.57) 0.11 (0.87, 0.38)
Trial arm 4 35.0 (30.5) 6.25 (24.5) 0.21 (0.35, 1.17) 0.26 (0.77, 1.13)
Trial arm 5 37.5 (21.0) 7.0 (20.3) 0.33 (1.10, 0.29) 0.35 (1.01, 0.35)
Intermittent (ﬁve arms combined) 42.9 (17.9) 2.5 (20.3) 0.14 (0.52 to 0.16) 0.12 (0.46 to 0.14)
Trial arm 1 43.2 (12.4) 1.04 (14.4) 0.08 (1.27, 0.82) 0.07 (1.44, 0.74)
Trial arm 2 51.25 (22.05) 6.25 (20.0) 0.28 (1.61, 0.24) 0.31 (1.13, 0.42)
Trial arm 3 34.4 (19.0) 1.04 (25.75) 0.06 (0.94, 0.73) 0.04 (1.04, 0.55)
Trial arm 4 38.5 (17.5) 4.69 (14.7) 0.27 (0.36, 1.25) 0.32 (0.60, 1.41)
Trial arm 5 47.9 (12.8) 10.0 (21.8) 0.78 (2.42, 0.36) 0.46 (1.35, 0.27)
Total (ﬁve arms combined) 39.5 (19.1) 3.3 (20.0) 0.17 (0.49 to 0.14) 0.17 (0.49 to 0.12)
Trial arm 1 41.2 (13.2) 4.8 (10.5) 0.36 (1.96, 0.14) 0.46 (1.73, 0.27)
Trial arm 2 48.9 (20.5) 6.6 (24.8) 0.32 (1.72, 0.49) 0.26 (1.06, 0.45)
Trial arm 3 29.2 (19.4) 0.8 (23.4) 0.04 (0.74, 0.67) 0.03 (1.01, 0.44)
Trial arm 4 36.9 (22.3) 5.4 (17.6) 0.25 (0.26, 1.34) 0.31 (0.58, 1.36)
Trial arm 5 43.2 (15.2) 8.6 (19.0) 0.57 (1.41, 0.27) 0.45 (1.56, 0.19)
WOMAC pain Five arms combined 42.0 (21.9) 2.8 (20.8) 0.13 (0.42, 0.14) 0.13 (0.44 to 0.15)
Trial arm 1 44.2 (11.8) 4.7 (6.6) 0.40 (1.60, 0.08) 0.72 (1.74, 0.17)
Trial arm 2 55.4 (26.0) 11.0 (23.8) 0.42 (1.33, 0.10) 0.46 (1.12, 0.31)
Trial arm 3 30.75 (20.1) þ3.8 (20.45) 0.19 (0.44, 0.81) 0.18 (0.66, 0.70)
Trial arm 4 41.45 (20.15) þ6.9 (22.2) 0.34 (0.51, 1.42) 0.30 (0.52, 1.81)
Trial arm 5 40.8 (23.0) 8.7 (22.7) 0.38 (1.18, 0.25) 0.38 (1.00, 0.36)
Hip OA (n ¼ 48) (n per treatment group: 1 n ¼ 8, 2 n ¼ 12, 3 n ¼ 12, 4 n ¼ 8, 5 n ¼ 10) e FUNCTION
WOMAC function Five arms combined 42.3 (23.5) 3.9 (20.9) 0.17 (0.43 to 0.06) 0.19 (0.46 to 0.07)
Trial arm 1 47.9 (20.5) 4.5 (6.9) 0.22 (1.54, 0.03) 0.65 (2.05, 0.09)
Trial arm 2 46.0 (26.8) 11.3 (24.5) 0.42 (1.12, 0.03) 0.46 (0.94, 0.12)
Trial arm 3 35.2 (25.0) þ1.7 (19.3) 0.07 (0.37, 0.56) 0.08 (0.69, 0.64)
Trial arm 4 39.5 (24.9) þ6.6 (19.2) 0.26 (0.26, 1.42) 0.34 (0.47, 1.22)
Trial arm 5 44.0 (20.6) 9.55 (25.0) 0.46 (1.95, 0.29) 0.38 (1.17, 0.27)
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Table III (continued )
Measure Baseline mean
scores (SD) (minemax)
Mean change
(SD)
Effect size (95% CI) Standardized response
mean (95% CI)
HOOSePS Five arms combined 30.3 (17.8) 3.0 (16.6) 0.17 (0.4 to 0.1) 0.18 (0.45 to 0.1)
Trial arm 1 39.6 (14.75) 10.3 (15.3) 0.70 (1.92, 0.03) 0.67 (1.77, 0.04)
Trial arm 2 33.7 (22.5) 11.2 (19.25) 0.50 (1.00, 0.12) 0.58 (1.30, 0.13)
Trial arm 3 22.6 (11.95) þ2.0 (12.96) 0.17 (0.49, 0.84) 0.16 (0.56, 0.79)
Trial arm 4 27.4 (22.5) þ7.7 (16.43) 0.34 (0.16, 1.09) 0.47 (0.26, 1.93)
Trial arm 5 30.4 (13.8) 2.0 (13.2) 0.14 (0.89, 0.54) 0.15 (0.85, 0.83)
*Indicates statistically signiﬁcant improvement from baseline values at P < 0.0001; **P < 0.01; ***P < 0.05.
y Trial treatment arms were: naproxcinod 750 mg, naproxcinod 375 mg, naproxen 500 mg, naproxen 250 mg, and ibuprofen 600 mg.
M. Bond et al. / Osteoarthritis and Cartilage 20 (2012) 541e547 545As noted earlier, ICOAP was developed to evaluate, separately,
the two distinct types of pain that patients with hip/knee OA
experience (i.e., intermittent and constant pain), independent of
the effect of OA on physical function. Using baseline scores for the
measures assessed, we conﬁrmed the very high correlation
between WOMAC pain and function scores both for individuals
with knee and hip OA (approximately 0.90 for both). In comparison,
the correlations between ICOAP scores and either measure of knee
function (WOMAC or KOOS) were substantially lower (0.75e0.81
and 0.51e0.62, respectively), indicating that the two new
measures are evaluating different constructs.
The original qualitative study from which the ICOAP was
developed also identiﬁed the predictability of the intermittent pain,
when present, as important to patients with hip and knee OA.
Participants reported that intense unpredictable intermittent pain
was most distressing, and most likely to impact their ability to
participate in valued activities. Unfortunately, intermittent pain
predictability was not assessed in this trial. Since initiation of this
trial, two predictability items have been developed and are being
administered alongside the two pain subscales in individuals who
report ‘pain that comes and goes’; thesemay be found on the OARSI
website (www.oarsi.org). These items ask about the frequency with
which their intermittent pain comes on ‘without warning’ and
‘after a trigger’ (from never to always). Ongoing research in
multiple longitudinal OA cohorts is evaluating the determinants
and outcomes associated with different OA pain patterns, including
the impact on treatment response, participation, demand for joint
replacement, and health care utilization. Coupled with ongoing
research to elucidate the role of peripheral and central sensitization
in painful OA, this research will be important in elucidating pain
phenotypes within OA, the ultimate goal of which is to improve the
targeting of pain interventions, and thus efﬁcacy with respect to
pain relief.
The HOOSePS and KOOSePS are shorter versions of the original
HOOS and KOOS measures18,19, which were designed to evaluate
a broader spectrum of physical function impairments in people
with hip and knee OA than has been previously demonstrated using
the WOMAC. In particular, the inclusion of items assessing sports-
related activity limitations aim at over-coming the previously
documented ﬂoor effects seen with the WOMAC function scale18.
The current study was not designed to address this aspect of the
new measures, and did not include the spectrum of individuals by
age or arthritis severity that would be required to do so. The current
study has, however, documented the responsiveness of the
KOOSePS in knee OA to pharmacologic intervention. As the
KOOSePS has fewer items (seven items)16 than either the original
WOMAC physical function scale (17 items)7 or the validated
WOMAC function short form (11 items)8,9, it may be less burden-
some for patients to complete20. Further research is needed to
compare these measures for use in higher functioning individuals,
such as those with sports-related knee injury, with respect to
ceiling and ﬂoor effects.As noted, no treatment response was observed overall, or by
treatment arm, for any measure, among hip OA trial participants.
Although inadequate power due to a small number of patients may
have limited our ability to detect meaningful changes following
treatment, non-response to therapeutic intervention26 and in the
placebo arms27 of controlled clinical trials of hip OA has also been
reported by others. This ﬁnding supports the evaluation of the
effect of pharmacologic interventions separately in individuals with
hip vs knee OA, as well as the need for research to better under-
stand why these differences in therapeutic response might
occur28,29.
Some study limitations should be noted in addition to those
above. First, the absence of signiﬁcant improvement in hip OA pain
and physical function precluded assessment of the responsiveness
of the new measures in hip OA. Second, this is the ﬁrst study to
examine the responsiveness of the new OARSIeOMERACT
measures in the context of OA pharmacologic therapeutic inter-
vention; additional studies are warranted to conﬁrm our ﬁndings,
and to tease out whether or not difference in response may occur
for individuals with different ICOAP pain patterns, incorporating
the concept of intermittent pain predictability.
In conclusion, ICOAP and KOOSePS have been shown to be
responsive to changes in pain and function following pharmaco-
logic intervention in OA. Additional research is warranted to
conﬁrm and elucidate explanations for differential therapeutic
response in patients with hip vs knee OA, and to conﬁrm the
responsiveness of the ICOAP, HOOSePS and KOOSePS in larger
samples of OA patients receiving myriad therapies, and across the
spectrum of OA symptom severity. Assuming these studies conﬁrm
the responsiveness of these new measures, studies are needed to
establish the degree of change associated with each measure that
patients consider meaningful (i.e., the minimal clinically important
difference). ICOAP is a multi-dimensional OA-speciﬁc measure
designed to evaluate the pain experience in peoplewith hip or knee
OA, including pain intensity, frequency and impact on mood, sleep
and quality of life, independent of the effect of pain on physical
function. Thus, ICOAP is intended to be used together with
a measure of physical function and should be seen as providing
information that is complementary to that provided by the
WOMAC pain scale, which largely evaluates pain on activity. For
assessment of physical function in OA, ongoing research will test
the hypothesis that, in high functioning individuals, such as those
with sports-related knee injury, use of the KOOSePS and HOOSePS
is associated with reduced ﬂoor and ceiling affects relative to the
WOMAC function subscale. If so, this would suggest these new
measures be used preferentially in this clinical setting.
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